Physician profile
Scott Lee
NPI 1699720946
$1,652.26
in general payments reported to CMS, 2019-2025
18 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $100 · 2021: $110 · 2022: $322 · 2023: $575 · 2024: $110 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $840.35 | 2019-2025 | Clareon, Centurion, Hydrus Microstent |
| Rxsight INC | $133.21 | 2023 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $108.04 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Istent Inject Trabecular Micro-Bypass System, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $91.26 | 2022-2025 | Cequa |
| Biotissue Holdings INC. | $87.17 | 2020-2022 | |
| Carl Zeiss Meditec, INC. | $57.55 | 2019 | |
| Genentech USA, INC. | $47.41 | 2023-2025 | Vabysmo |
| Thea Pharma INC. | $42.82 | 2024-2025 | Iyuzeh |
| Omeros Corporation | $38.25 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $30.71 | 2019-2020 | |
| Allergan, INC. | $25.16 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $23.28 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $23.11 | 2023 | Tepezza |
| Ocular Therapeutix, INC. | $22.43 | 2021 | |
| Mallinckrodt Enterprises LLC | $21.44 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.52 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.15 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.